Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain

Metastases represent the most common brain tumors in adults. Surgical resection alone results in 45% recurrence and is usually accompanied by radiation and chemotherapy. Adequate chemotherapy delivery to the CNS is hindered by the blood–brain barrier. Efforts at delivering chemotherapy locally to gliomas have shown modest increases in survival, likely limited by the infiltrative nature of the tumor. Temozolomide (TMZ) is first-line treatment for gliomas and recurrent brain metastases. Doxorubicin (DOX) is used in treating many types of breast cancer, although its use is limited by severe cardiac toxicity. Intracranially implanted DOX and TMZ microcapsules are compared with systemic administration of the same treatments in a rodent model of breast adenocarcinoma brain metastases. Outcomes were animal survival, quantified drug exposure, and distribution of cleaved caspase 3. Intracranial delivery of TMZ and systemic DOX administration prolong survival more than intracranial DOX or systemic TMZ. Intracranial TMZ generates the more robust induction of apoptotic pathways. We postulate that these differences may be explained by distribution profiles of each drug when administered intracranially: TMZ displays a broader distribution profile than DOX. These microcapsule devices provide a safe, reliable vehicle for intracranial chemotherapy delivery and have the capacity to be efficacious and superior to systemic delivery of chemotherapy. Future work should include strategies to improve the distribution profile. These findings also have broader implications in localized drug delivery to all tissue, because the efficacy of a drug will always be limited by its ability to diffuse into surrounding tissue past its delivery source.National Institutes of Health (U.S.) (Grant R01 EB006365-06)Brain Science Foundation (Private Grant 106708

A new Myxidium species (Myxozoa: Myxosporea) infecting the gallbladder of the turtle Podocnemis unifilis (Testudines: Podocnemididae) from Peruvian Amazon

A new myxosporean species, Myxidium peruviensis n. sp., is described parasitizing the gall bladder of the yellow spotted river turtle Podocnemis unifilis kept in captivity in an Amazonian Peruvian turtle rescue unit in the city of Iquitos, State of Loreto, Peru. The parasite was found in four of ten (40%) P. unifilis examined. The new species was characterized based on morphological and molecular phylogeny analyses. SSU rDNA sequence of the spores of M. peruviensis n. sp. resulted in 1876 nucleotides and this sequence did no match any of the Myxozoa available in the GenBank. Phylogenetic analysis identified the new species as a sister species of Myxidium turturibus, the unique Myxidium species described in a Neotropical turtle. Nevertheless, the SSU rDNA sequences of the new species and M. turturibus have only a 91.5% similarity. This is the first description and molecular study of a Myxozoa in a reptile from Peru. Considering the status of P. unifilis as vulnerable species, the infection by Myxidium parasites is emphasized as possible disease impeller, representing menace to the turtle conservation.Sao Paulo Research Foundation, FAPESPNatl Univ San Marcos, Lab Biol & Mol Genet, Fac Vet Med, Lima 2800, PeruUniv Fed Sao Paulo, Paulista Sch Med, Dept Biophys, BR-04023062 Sao Paulo, BrazilFed Inst Educ Sci & Technol, Fac Biol Sci, BR-01109010 Sao Paulo, BrazilUniv Estadual Campinas, Inst Biol, Dept Anim Biol, Ave Bertrand Russel S-N,Cx 6109, BR-13083970 Campinas, SP, BrazilUniv Fed Sao Paulo, Paulista Sch Med, Dept Biophys, BR-04023062 Sao Paulo, BrazilFAPESP: 2015/23948-5FAPESP: 2016/25919-5Web of Scienc

Cranberry juice consumption may reduce biofilms on uroepithelial cells: Pilot study in spinal cord injured patients

Aims: To determine the ability of probiotic lactobacilli to improve the treatment of vulvovaginal candidiasis (VVC) using a randomized, double-blind and placebo-controlled trial. Methods and Results: Fifty-five women diagnosed with VVC by vaginal discharge positive for Candida spp. (according to culture method) associated with at least one of the symptoms (itching and burning vaginal feeling, dyspareunia and dysuria), were treated with single dose of fluconazole (150 mg) supplemented every morning for the following 4 weeks with two placebo or two probiotic capsules (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14). At 4 weeks, the probiotic treated group showed significantly less vaginal discharge associated with any of the above mentioned symptoms (10·3%vs 34·6%; P = 0·03) and lower presence of yeast detected by culture (10·3%vs 38·5%; P = 0·014). Conclusion: This study has shown that probiotic lactobacilli can increase the effectiveness of an anti-fungal pharmaceutical agent in curing disease. Significance and Impact of the Study: This novel finding of probiotic lactobacilli augmenting the cure rate of yeast vaginitis, not only offers an alternative approach to a highly prevalent condition that adversely affects the quality of life of women around the world, but also raises the question of how this combination works. © 2009 The Society for Applied Microbiology

Characterization of new small ruminant lentivirus subtype B3 suggests animal trade within the Mediterranean Basin

Small ruminant lentiviruses (SRLVs) represent a group of viruses infecting sheep and goats worldwide. Despite the high heterogeneity of genotype A strains, which cluster into as many as ten subtypes, genotype B was believed to be less complex and has, so far, been subdivided into only two subtypes. Here, we describe two novel full-length proviral sequences isolated from Sarda sheep in two Italian regions. Genome sequence as well as the main linear epitopes clearly placed this cluster into genotype B. However, owing to long-standing segregation of this sheep breed, the genetic distances that are clearly .15% with respect to B1 and B2 subtypes suggest the designation of a novel subtype, B3. Moreover the close relationship with a gag sequence obtained from a Turkish sheep adds new evidence to historical data that suggest an anthropochorous dissemination of hosts (small ruminants) and their pathogens (SRLV) during the colonization of the Mediterranean from the Middle East

Current scientific understanding of urinary tract infections in women: An overview

Bacterial vaginosis (BV) is the most prevalent vaginal infection worldwide and is characterized by depletion of the indigenous lactobacilli. Antimicrobial therapy is often ineffective. We hypothesized that probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 might provide an adjunct to antimicrobial treatment and improve cure rates. Sixty-four Brazilian women diagnosed with BV were randomly assigned to receive a single dose of tinidazole (2 g) supplemented with either 2 placebo capsules or 2 capsules containing L. rhamnosus GR-1 and L. reuteri RC-14 every morning for the following 4 weeks. At the end of treatment (day 28), the probiotic group had a significantly higher cure rate of BV (87.5%) than the placebo group (50.0%) (p = 0.001). In addition, according to the Gram-stain Nugent score, more women were assessed with normal vaginal microbiota in the probiotic group (75.0% vs. 34.4% in the placebo group; p = 0.011). This study shows that probiotic lactobacilli can provide benefits to women being treated with antibiotics for an infectious condition